TapewireFind a company

person · Reporting owner

Francis Richard D

Disclosed activity across 2 companies

Tapewire entity
40715
SEC CIK
0001673277

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
METTLER TOLEDO INTERNATIONAL INC/MTD · Entity 3168DirectorNovember 12, 2024November 14, 2024
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063President and CEOJune 05, 2026June 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

METTLER TOLEDO INTERNATIONAL INC/

Report date November 12, 2024 · Filed November 14, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivativeDirect624 Reported balance After 2024-11-12 transaction · row 1
1 source row

Row 1 · 2024-11-12 · Grant · Acquired 71 · Balance 624

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,260.97 · Expires 2034-11-12Direct182 Reported balance After 2024-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-11-12 · Grant · Acquired 182 · Balance 182

F1: The options vest annually in two equal installments beginning on the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest annually in two equal installments beginning on the first anniversary of the date of grant.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date June 05, 2026 · Filed June 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect1,177,529 Last balance in matching sequence After 2026-06-05 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-06-05 · Exercise / conversion · Acquired 13,043 · Balance 1,183,682

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Row 2 · 2026-06-05 · Sale · Disposed 6,153 · Balance 1,177,529

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Restricted Share UnitsSEC Table II · derivative / convertible securityDirect39,130 Reported balance After 2026-06-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-05 · Exercise / conversion · Disposed 13,043 · Balance 39,130

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 05, 2026 Filed Jun 8, 2026 20:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,043 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-261660 · ownership.xml · derivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,130

Underlying: Ordinary Shares · 13,043 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.

F5 · derivative.expiration_date: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,153 $34.35 $211,355.55
Disclosure

SEC source: 0001193125-26-261660 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,177,529

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,043 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-261660 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,183,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 42,452 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-098551 · ownership.xml · derivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 127,359

Underlying: Ordinary Shares · 42,452 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 42,452 vested on March 5, 2026, 42,452 vesting on each of March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029.

F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 42,452 vested on March 5, 2026, 42,452 vesting on each of March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 20,025 $31.67 $634,159.71
Disclosure

SEC source: 0001193125-26-098551 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,170,639

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:18 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 42,452 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-098551 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,190,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 136,736 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096591 · ownership.xml · derivative · entry 4

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,736

Underlying: Ordinary Shares · 136,736 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 34,184 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 34,184 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 50,223 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096591 · ownership.xml · derivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,446

Underlying: Ordinary Shares · 50,223 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on each of March 4, 2025 and March 4, 2026, and 50,223 vesting on each of March 4, 2027 and March 4, 2028.

F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on each of March 4, 2025 and March 4, 2026, and 50,223 vesting on each of March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 23,393 $32.46 $759,442.05
Disclosure

SEC source: 0001193125-26-096591 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,148,212

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 50,223 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096591 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,171,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 891,315 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093916 · ownership.xml · derivative · entry 6

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 891,315 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

F7 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 67,231 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093916 · ownership.xml · derivative · entry 5

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,231

Underlying: Ordinary Shares · 67,231 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 67,231 vesting on March 3, 2027.

F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 67,231 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 412,032 $32.36 $13,333,314.32
Disclosure

SEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 4

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,121,382

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 891,315 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,533,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 30,903 $32.36 $1,000,017.99
Disclosure

SEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 642,099

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 67,231 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 673,002

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 620,110 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-056996 · ownership.xml · derivative · entry 6

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 620,110 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on February 15, 2026, following satisfaction of the time-based vesting criteria.

F7 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on February 15, 2026, following satisfaction of the time-based vesting criteria.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 161,656 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-056996 · ownership.xml · derivative · entry 5

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 161,656 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 15, 2023, with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vested on February 15, 2026.

F6 · derivative.expiration_date: Restricted share units were granted on February 15, 2023, with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vested on February 15, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 286,122 $34.22 $9,792,267.94
Disclosure

SEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 4

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 605,771

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.015 to $34.51, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 620,110 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 891,893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 161,656 $34.22 $5,532,531.11
Disclosure

SEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,783

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

F4 · shares: Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.015 to $34.51, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 161,656 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 433,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 891,315 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-029300 · ownership.xml · derivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 891,315

Underlying: Ordinary Shares · 891,315 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

F4 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 620,110 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-029300 · ownership.xml · derivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 620,110

Underlying: Ordinary Shares · 620,110 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted shares units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 15, 2026.

F2 · derivative.expiration_date: Represents restricted shares units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 15, 2026.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 52,173 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-083680 · ownership.xml · derivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,173

Underlying: Ordinary Shares · 52,173 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2025, with 13,043 vesting on each of June 5, 2026, June 5, 2027, and June 5, 2028 and 13,044 vesting on June 5, 2029.

F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2025, with 13,043 vesting on each of June 5, 2026, June 5, 2027, and June 5, 2028 and 13,044 vesting on June 5, 2029.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 6, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 8,259 $15.91 $131,427.12
Disclosure

SEC source: 0000950170-25-034583 · ownership.xml · nonDerivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,783

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 169,811 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035467 · ownership.xml · derivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,811

Underlying: Ordinary Shares · 169,811 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 42,452 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029.

F2 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 42,452 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 5, 2025 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,450 $15.56 $100,346.52
Disclosure

SEC source: 0000950170-25-033515 · ownership.xml · nonDerivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,333

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.455 to $15.75, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 50,223 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034583 · ownership.xml · derivative · entry 4

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,669

Underlying: Ordinary Shares · 50,223 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on March 4, 2025, and 50,223 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on March 4, 2025, and 50,223 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 15,514 $15.73 $244,106.58
Disclosure

SEC source: 0000950170-25-034583 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 280,042

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 50,223 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034583 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 295,556

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 67,231 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-033515 · ownership.xml · derivative · entry 4

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,462

Underlying: Ordinary Shares · 67,231 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024 and March 3, 2025, and 67,231 vesting on each of March 3, 2026 and March 3, 2027.

F7 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024 and March 3, 2025, and 67,231 vesting on each of March 3, 2026 and March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 24,892 $16.19 $402,889.47
Disclosure

SEC source: 0000950170-25-033515 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 251,783

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.86 to $16.53, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 67,231 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-033515 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 276,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 75,506 $16.95 $1,279,660.59
Disclosure

SEC source: 0000950170-25-023126 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 209,444

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.885 to $17.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 15, 2025 Filed Feb 19, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 161,655 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-023126 · ownership.xml · derivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,656

Underlying: Ordinary Shares · 161,655 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 15, 2023 with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.

F6 · derivative.expiration_date: Restricted share units were granted on February 15, 2023 with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 15, 2025 Filed Feb 19, 2025 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 161,655 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-023126 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 284,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
November 12, 2024 Filed Nov 14, 2024 18:35 UTC METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 GrantStock Option (right to buy) · Derivative 182 $0.00 Strike: $1,260.97 $0.00
Disclosure

SEC source: 0001062993-24-019115 · form4.xml · derivative · entry 2

Francis Richard D · CIK 0001673277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182

Underlying: Common Stock, par value $0.01 per share · 182 shares

Expires 2034-11-12

F1 · derivative.exercise_date: The options vest annually in two equal installments beginning on the first anniversary of the date of grant.

Read SEC document
November 12, 2024 Filed Nov 14, 2024 18:35 UTC METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 GrantCommon Stock, par value $0.01 per share 71 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-019115 · form4.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 624

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 200,892 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026008 · ownership.xml · derivative · entry 4

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,892

Underlying: Ordinary Shares · 200,892 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 50,223 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028.

F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 50,223 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 31,061 $13.34 $414,269.88
Disclosure

SEC source: 0000950170-24-026008 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,295

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 67,231 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026008 · ownership.xml · derivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,693

Underlying: Ordinary Shares · 67,231 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.

F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 67,231 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026008 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,356

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 12:42 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 161,655 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016803 · ownership.xml · derivative · entry 3

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 323,311

Underlying: Ordinary Shares · 161,655 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.

F6 · derivative.expiration_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 12:42 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 74,530 $13.15 $980,173.84
Disclosure

SEC source: 0000950170-24-016803 · ownership.xml · nonDerivative · entry 2

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,125

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $13.24, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 12:42 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 161,655 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-016803 · ownership.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
November 09, 2023 Filed Nov 13, 2023 13:45 UTC METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 GrantStock Option (right to buy) · Derivative 250 $0.00 Strike: $1,024.55 $0.00
Disclosure

SEC source: 0001062993-23-020526 · form4.xml · derivative · entry 2

Francis Richard D · CIK 0001673277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250

Underlying: Common Stock, par value $0.01 per share · 250 shares

Expires 2033-11-09

F1 · derivative.exercise_date: The options vest annually in two equal installments beginning on the first anniversary of the date of grant.

Read SEC document
November 09, 2023 Filed Nov 13, 2023 13:45 UTC METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 GrantCommon Stock, par value $0.01 per share 49 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-020526 · form4.xml · nonDerivative · entry 1

Francis Richard D · CIK 0001673277 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 553

Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:06 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 268,924 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016701 · doc4.xml · derivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,924

Underlying: Ordinary Shares · 268,924 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.

F2 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 15, 2023 Filed Feb 17, 2023 12:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 484,966 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-010333 · doc4.xml · derivative · entry 1

Francis Richard D · CIK 0001673277 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 484,966

Underlying: Ordinary Shares · 484,966 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.

F2 · derivative.expiration_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.